Company Overview

Damian Pharma is a privately-held pharmaceutical company incorporated in  2014 in Switzerland, with access to one of the largest networks of Life Science companies, service providers and business Experts.  Led by an experienced team of pharmaceutical Executives, Damian Pharma focuses on creating value that benefits patients and shareholders.

Project Overview

The primary goal of Damian Pharma is the development of new investigational medical entities for the treatment of patients with rare endocrine disorders.  Damian Pharma has identified and characterized DP13; the Phase 1 trial for DP13 is currently recruiting (www.clinicaltrials.gov identifier:  NCT # 030465890).